Opportunities and Challenges for Host-Directed Therapies in Tuberculosis

E-ISSN： 1873-4286|22|17|2599-2604

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.17, 2016-05, pp. : 2599-2604

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Host-directed therapy of tuberculosis: what is in it for microRNA?

By Iannaccone Marco Dorhoi Anca Kaufmann Stefan HE

Expert Opinion on Therapeutic Targets, Vol. 18, Iss. 5, 2014-05 ,pp. : 491-494

Informa Healthcare

Access to resources Recommend Favorite

Identifying the challenges of biomarkers that predict response to HER2-directed therapies

By Iyengar Neil M Morris Patrick G

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 11, 2013-08 ,pp. : 1437-1440

Informa Healthcare

Access to resources Recommend Favorite

Liver-Directed Therapies for Hepatocellular Carcinoma

By Arciero Cletus A. Sigurdson Elin R.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 8, 2006-09 ,pp. : 768-774

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Tuberculosis: Challenges to Improve the Treatment

Current Clinical Pharmacology, Vol. 10, Iss. 3, 2015-01 ,pp. : 242-251

Bentham Science Publishers

Access to resources Recommend Favorite

NNRTIs: challenges and opportunities

Inpharma, Vol. 1, Iss. 1347, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite